Request Demo

Last update 08 May 2025

Acrodynia

Last update 08 May 2025

Basic Info

Synonyms

ACRODYNIA, Acrodynia, Acrodynia caused by mercury

+ [65]

Introduction

A condition seen primarily in childhood, most often resulting from chronic exposure to MERCURY COMPOUNDS which may result in encephalopathy and POLYNEUROPATHY. Clinical features include pain, swelling and pinkish discoloration of the fingers and toes, weakness in the extremities, extreme irritability, HYPERESTHESIA, and alterations in level of consciousness. (From Menkes, Textbook of Child Neurology, 5th ed, p603)

Clinical Trials associated with Acrodynia

CTR20222474

/ CompletedNot Applicable

西洛他唑片在健康受试者中随机、开放、单次给药、两制剂、两周期、双交叉空腹状态下生物等效性试验

[Translation] A randomized, open-label, single-dose, two-formulation, two-period, double-crossover bioequivalence study of cilostazol tablets in healthy subjects under fasting conditions

主要研究目的研究空腹状态下单次口服受试制剂西洛他唑片（规格：50 mg，四川美大康华康药业有限公司生产，宏越科技（湖州）有限公司提供）与参比制剂西洛他唑片（Pletal®，规格：50 mg；由Teva Pharmaceuticals USA Inc持证，宏越科技（湖州）有限公司提供）在健康成年受试者体内的药代动力学，评价空腹状态口服两种制剂的生物等效性。次要研究目的研究受试制剂西洛他唑片和参比制剂西洛他唑片（Pletal®）在健康成年受试者中的安全性。

[Translation]

Main study objectives To study the pharmacokinetics of the test preparation Cilostazol Tablets (Specification: 50 mg, produced by Sichuan Meida Kanghuakang Pharmaceutical Co., Ltd., provided by Hongyue Technology (Huzhou) Co., Ltd.) and the reference preparation Cilostazol Tablets (Pletal®, Specification: 50 mg; licensed by Teva Pharmaceuticals USA Inc, provided by Hongyue Technology (Huzhou) Co., Ltd.) in healthy adult subjects after a single oral administration in the fasting state, and to evaluate the bioequivalence of the two preparations when taken orally in the fasting state. Secondary study objectives To study the safety of the test preparation Cilostazol Tablets and the reference preparation Cilostazol Tablets (Pletal®) in healthy adult subjects.

Start Date09 Oct 2022

Sponsor / Collaborator

Hongyue Technology (Huzhou) Co., Ltd.

CTR20222194

/ CompletedNot Applicable

中国健康受试者空腹单次口服西洛他唑片的随机、开放、二周期、交叉设计的人体生物等效性试验

[Translation] A randomized, open-label, two-period, crossover-designed bioequivalence study of a single oral dose of cilostazol tablets in Chinese healthy subjects on an empty stomach

主要目的：研究中国健康受试者空腹单剂量口服浙江永宁药业股份有限公司研制的西洛他唑片（希若宁®）后的血药浓度经时过程，估算相应的药代动力学参数，并以Teva Pharmaceuticals USA, Inc生产的西洛他唑片为参比制剂，进行生物等效性评价；次要研究目的：观察受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

Primary objective: To study the time course of blood drug concentration of cilostazol tablets (Xiruoning®) developed by Zhejiang Yongning Pharmaceutical Co., Ltd. after a single oral dose on an empty stomach in healthy Chinese subjects, estimate the corresponding pharmacokinetic parameters, and use cilostazol tablets produced by Teva Pharmaceuticals USA, Inc as the reference preparation for bioequivalence evaluation; Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy subjects.

Start Date19 Sep 2022

Sponsor / Collaborator

Zhejiang Yongning Pharmaceutical Co. Ltd.

CTR20221851

/ CompletedNot Applicable

西洛他唑片在健康受试者中随机、开放、单次给药、双周期、两剂量、双交叉空腹状态下生物等效性试验

[Translation] A randomized, open-label, single-dose, two-period, two-dose, double-crossover bioequivalence study of cilostazol tablets in healthy subjects under fasting conditions

主要研究目的研究空腹状态下单次口服受试制剂西洛他唑片（规格：50 mg，华益药业科技（安徽）有限公司生产，杭州沐源生物医药科技有限公司提供）与参比制剂西洛他唑片（Pletal®，规格：50 mg；Teva Pharmaceuticals USA Inc生产，杭州沐源生物医药科技有限公司提供）在健康成年受试者体内的药代动力学，评价空腹状态口服两种制剂的生物等效性。次要研究目的研究受试制剂西洛他唑片和参比制剂西洛他唑片（Pletal®）在健康成年受试者中的安全性。

[Translation]

Main study objectives To study the pharmacokinetics of the test preparation Cilostazol Tablets (Specification: 50 mg, produced by Huayi Pharmaceutical Technology (Anhui) Co., Ltd., provided by Hangzhou Muyuan Biopharmaceutical Technology Co., Ltd.) and the reference preparation Cilostazol Tablets (Pletal®, Specification: 50 mg; produced by Teva Pharmaceuticals USA Inc, provided by Hangzhou Muyuan Biopharmaceutical Technology Co., Ltd.) in healthy adult subjects after a single oral administration in the fasting state, and to evaluate the bioequivalence of the two preparations when taken orally in the fasting state. Secondary study objectives To study the safety of the test preparation Cilostazol Tablets and the reference preparation Cilostazol Tablets (Pletal®) in healthy adult subjects.

Start Date08 Aug 2022

Sponsor / Collaborator

Hangzhou Muyuan Biomedical Technology Co., Ltd.

100 Clinical Results associated with Acrodynia

100 Translational Medicine associated with Acrodynia

0 Patents (Medical) associated with Acrodynia

562

Literatures (Medical) associated with Acrodynia

01 Feb 2025·JAAD Case Reports

Asymptomatic pink nodules in an African-American woman

Article

Author: Farabi, Banu ; Adam, Richard ; Roster, Katie ; Shulman, Kenneth

01 Dec 2024·Plant Disease

First Report of Potato Pink Rot Caused by Phytophthora erythroseptica in Colorado

Article

Author: Chikh-Ali, Mohamad ; Daniel, Jeremy

Pink rot, caused by the oomycete Phytophthora erythroseptica, is a serious disease that may cause substantial losses to potato growers. In 2023, high infection rates of pink rot were noticed in the San Luis Valley (SLV), Colorado around harvest time and in storage with several growers losing complete storage pins to pink rot. In September 2023, tubers with pink rot symptoms were collected from two grower fields of Russet Norkotah (~2-3% infection) and Canela Russet (~5% infection) near the San Luis Valley Research Center at harvest time. Infected tubers showed dark discoloration on the surface at the stem end. Upon cutting, affected tissue developed salmon pink color about 20-30 min later (Fig. 1). DNA was extracted from two symptomatic tubers from each cultivar and healthy tubers using DNeasy PowerSoil Pro Kit (Qiagen, MD, USA) according to the manufacturer’s instructions. The conventional PCR and qPCR assays developed by Cullen et al. (2007) were used to detect P. erythroseptica. In the conventional PCR, the primer pair Pery2F1/R1 produced expected bands of 135bp from symptomatic tubers but not from the healthy tubers. The symptomatic tubers were positive in the qPCR using the primer-probe set 99F, 177R, and 133T (Cullen et al., 2007). P. erythroseptica was isolated by culturing specimens of infected tissues on PARP selective media (Jeffers and Martin, 1986). A week later colonies of white color grew on the media. These colonies were confirmed to be of P. erythroseptica by PCR as mentioned above. The colonies of two isolates were transferred to water agar media, then three days later a mycelium tip was excised and cultured on PDA media for single isolation. On PDA media the colonies showed chrysanthemum pattern. Four days later DNA was extracted from the two isolates, RN296-1 and Canela-2, and tested positive for P. erythroseptica by the above-mentioned PCR. PDA agar plugs of two isolates were used to inoculate surface sterilized potato tubers. The isolate SLV-2023-Canela2 was inoculated on tubers of Russet Norkotah and Reveille Russet, 10 each, while10 tubers of Russet Norkotah were inoculated with the isolate SLV-2023-RN296-1. Ten tubers of Russet Norkotah were inoculated by sterilized plugs of PDA for negative controls. Tubers were left at room temperature for a week. All tubers of Russet Norkotah inoculated with SLV-2023-Canela2 and RN296-4 developed pink rot symptoms and tested positive for P. erythroseptica by PCR, while only 9 tubers of Reveille Russet inoculated with SLV-2023-Canela2 developed symptoms and were positive to P. erythroseptica by PCR. No symptoms were observed on the mock inoculated tubers and no P. erythroseptica was detected by the PCR. P. erythroseptica was isolated again from Russet Norkotah tubers inoculated with RN296-1 on PDA media and tested positive for P. erythroseptica by PCR one week later. To further confirm the identity, the ITS region was amplified using the primers ITS-1 and ITS-4 (White et al., 1990) from DNA extracted from inoculated Russet Norkotah tubers with SLV-2023-Canela2 isolate. PCR product was purified using QIAquick Gel Extraction Kit (Qiagen, MD, USA)and cloned using TOPO TA Cloning Kit for Sequencing (Invitrogen, MD, USA). Four clones were submitted for sequencing. The 846 nt sequence of the ITS was submitted to the GenBank (accession number PP587391) shared 99.76% identity with the P. erythroseptica strain BBA 62683 (KJ755119). P. erythroseptica was identified previously using morphological tools from tubers with symptoms resembling pink rot collected in the SLV (Tyler et al., 2002). However, in that report neither Koch's Postulates, nor molecular identification were conducted, hence, the current study presents the first molecular report of pink rot in the SLV, Colorado. Rapidly changing climate and increased temperature around harvest time may lead to an increase in the incidence of pink rot, hence effective management strategies need to be developed and implemented.

01 Aug 2024·Pediatric Infectious Disease Journal

Intravenous Immunoglobulin in Diphtheritic Polyneuropathy

Letter

Author: Boue, Yvonnick ; Toubiana, Julie ; Franco, Justine ; Brisse, Sylvain ; Van Goethem, Tania ; Kerambrun, Hugo ; Chamouine, Abdourahim

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Acrodynia

Basic Info

Related

Analysis